Novo Nordisk A/S

PharmaceuticalsFounded 1989

Market Data Current As Of: September 12, 2026

Related Competitor Intelligence

Compare market positioning with top industry peers

Competitor

Explore Novo Nordisk A/S

Core profile pages, annual revenue records, and related research hubs for this company.

Novo Nordisk A/S

PharmaceuticalsFounded 1989

Reviewed by Swet Parvadiya

Last reviewed: September 12, 2026

Market Data Current As Of: September 12, 2026

Financial Performance

Novo Nordisk A/S Revenue & Financials

Name: Novo Nordisk A/S Annual Revenue History
Creator: CorpDigest
License: https://corpdigest.com/terms

Revenue

DKK 309.1B (about $46.0B)

Market Cap

$450.2B

Net Income

$15.2B

Employees

64,000

Financial Analysis

Novo Nordisk is operating as the undisputed sovereign of the explosive global obesity and diabetes market. Under CEO Lars Fruergaard Jørgensen, the Danish pharmaceutical titan generated exactly $33.7 billion in revenue and maintains a $450.2 billion market cap with exactly 64000 employees. The financial narrative in 2026 is entirely defined by unprecedented, voracious consumer demand; functioning in a perpetual state of severe supply shortage, Novo Nordisk extracts wildly compounding margins as desperate patients exhaust its manufacturing capacity for GLP-1 weight-loss blockbusters Ozempic and Wegovy.

Revenue Trend Analysis

YoY Change

+7.7%

2-Year CAGR

+16.3%

Peak Year

2025

Trend

Consistent Growth

Novo Nordisk A/S has reported revenue across 3 fiscal years, compounding at +16.3% annually over 2 years. The most recent year saw a 7.7% increase versus the prior year. Revenue peaked in 2025 at $46.0B. Out of 2 reported periods, 2 showed growth and 0 showed a decline.

Annual Revenue History

Fiscal Year	Revenue	Net Income	YoY Change
FY2025	$46.0B	$15.2B	+7.7%
FY2024	$42.7B	$14.3B	+25.6%
FY2023	$34.0B	$12.2B	—

Source: SEC EDGAR filings, annual earnings releases, and verified financial disclosures.

Click any row to see year details.

Related Companies

Eli Lilly and Company Novartis AG Bausch Health Companies Inc.

Compare Novo Nordisk A/S Revenue With Competitors

Novo Nordisk A/S vs Eli Lilly and Company →Novo Nordisk A/S vs Novartis AG →Novo Nordisk A/S vs Bausch Health Companies Inc. →

Novo Nordisk A/S Revenue and Financial FAQ

What was Novo Nordisk A/S's reported annual revenue for FY2025?

Novo Nordisk A/S reported approximately $33.7B in fiscal year 2025 with a team of 64,000 employees worldwide.

How does Novo Nordisk A/S allocate capital and manage operating margins?

Novo Nordisk A/S strategically balances reinvestment into core R&D with operational cost discipline, focusing on workflow automation to expand operating margins in 2026.

What is the long-term financial outlook for Novo Nordisk A/S in Pharmaceuticals, Diabetes Care, Obesity Care, GLP-1 Medicines, and Rare Disease?

Financial performance in Pharmaceuticals, Diabetes Care, Obesity Care, GLP-1 Medicines, and Rare Disease is driven by steady cash generation and pricing power, enabling Novo Nordisk A/S to reinvest in high-return strategic initiatives.

Cite or embed this data

Using these figures? Please credit CorpDigest with a link.

Cite this page

CorpDigest. "Novo Nordisk A/S Revenue & Financials." CorpDigest, https://corpdigest.com/company/novo-nordisk/financials.

Embed this data

<div style="font-family:system-ui,sans-serif;font-size:14px;line-height:1.5;border:1px solid #e2e8f0;border-radius:8px;padding:12px 16px;max-width:520px"><strong>Novo Nordisk A/S reported $46B in revenue (FY2025).</strong><br>Source: <a href="https://corpdigest.com/company/novo-nordisk/financials" target="_blank" rel="noopener">CorpDigest — Novo Nordisk A/S financials</a></div>

Related Competitor Intelligence

Compare market positioning with top industry peers

Competitor

Eli Lilly and Company

View Competitor Intelligence

Competitor

Novartis AG

View Competitor Intelligence

Competitor

Bausch Health Companies Inc.

View Competitor Intelligence

Competitor

Pfizer

View Competitor Intelligence

Competitor

Johnson And Johnson

View Competitor Intelligence

Competitor

Gsk

View Competitor Intelligence

Explore Novo Nordisk A/S

Core profile pages, annual revenue records, and related research hubs for this company.

Financial Analysis

Fiscal Year

Revenue

Net Income

YoY Change

FY2025

$46.0B

$15.2B

+7.7%

FY2024

$42.7B

$14.3B

+25.6%

FY2023

$34.0B

$12.2B

—

Novo Nordisk A/S Revenue and Financial FAQ

What was Novo Nordisk A/S's reported annual revenue for FY2025?

Novo Nordisk A/S reported approximately $33.7B in fiscal year 2025 with a team of 64,000 employees worldwide.

How does Novo Nordisk A/S allocate capital and manage operating margins?

Novo Nordisk A/S strategically balances reinvestment into core R&D with operational cost discipline, focusing on workflow automation to expand operating margins in 2026.

What is the long-term financial outlook for Novo Nordisk A/S in Pharmaceuticals, Diabetes Care, Obesity Care, GLP-1 Medicines, and Rare Disease?

Cite or embed this data

Using these figures? Please credit CorpDigest with a link.

Cite this page

CorpDigest. "Novo Nordisk A/S Revenue & Financials." CorpDigest, https://corpdigest.com/company/novo-nordisk/financials.

Embed this data

<div style="font-family:system-ui,sans-serif;font-size:14px;line-height:1.5;border:1px solid #e2e8f0;border-radius:8px;padding:12px 16px;max-width:520px"><strong>Novo Nordisk A/S reported $46B in revenue (FY2025).</strong><br>Source: <a href="https://corpdigest.com/company/novo-nordisk/financials" target="_blank" rel="noopener">CorpDigest — Novo Nordisk A/S financials</a></div>